offline
Merck 4Q net powered by cancer treatment sales, lower taxes
Higher medicine sales and lower restructuring and other costs lifted drugmaker Merck to a $1.83 billion profit in the fourth quarter, as it edged past Wall Street expectations.
The maker of blockbuster cancer drug Keytruda and Januvia diabetes pills lost $1.05 billion a year earlier, when it had a $2.92 billion tax bill due to a federal tax overhaul.
...
The Kenilworth, New Jersey, drugmaker on Friday reported net income of 69 cents per share. Adjusted for multiple non-recurring costs, that amounted to $2.75 billion, or $1.04 per share, a penny better than analysts expected.
Revenue was $11 billion, slightly better than expected and up 5 percent from $10.43 billion in 2017's last quarter. Merck said unfavorable currency exchange rates reduced revenue by 3 percent in the quarter.
...
https://finance.yahoo.com/news/merck-4q-...ccounter=1
![[Bild: MRKc1dl1642.png]](https://finviz.com/publish/020119/MRKc1dl1642.png)
Higher medicine sales and lower restructuring and other costs lifted drugmaker Merck to a $1.83 billion profit in the fourth quarter, as it edged past Wall Street expectations.
The maker of blockbuster cancer drug Keytruda and Januvia diabetes pills lost $1.05 billion a year earlier, when it had a $2.92 billion tax bill due to a federal tax overhaul.
...
The Kenilworth, New Jersey, drugmaker on Friday reported net income of 69 cents per share. Adjusted for multiple non-recurring costs, that amounted to $2.75 billion, or $1.04 per share, a penny better than analysts expected.
Revenue was $11 billion, slightly better than expected and up 5 percent from $10.43 billion in 2017's last quarter. Merck said unfavorable currency exchange rates reduced revenue by 3 percent in the quarter.
...
https://finance.yahoo.com/news/merck-4q-...ccounter=1
__________________
